Author: Mitchell Gaydash
August 2023 Newsletter
August 24, 2023ToxTracker is a unique, stem-cell based assay which takes advantage of a Green Fluorescent Protein (GFP) reporter system to identify hazard and mode-of-action (MOA) of potentially genotoxic materials. On July 20th, IIVS was formally awarded ToxTracker Certification by Toxys, a Dutch Biotechnology company and the developers of the assay....
IIVS Acquires Licenses to Work with DEA Schedule I Materials
July 29, 2023IIVS is pleased to announce that our lab has acquired the necessary State and Federal licenses required to work with several materials and compounds listed on DEA Schedule 1. These include cannabis and Δ9-THC and related cannabinoids (DEA Drug Codes 7360 & 7370). Our state-of-the art exposure systems include the Vitrocell® VC-1 and Cloud which able to generate smoke and nebulize liquid formulations and permit IIVS to evaluate controlled substance-containing products for many respiratory endpoints, such as cytotoxicity, inflammatory response...
Multiscale Stiffness of Human Emphysematous Precision-Cut Lung Slices
May 22, 2023IIVS is excited to announce a new publication in Science with co-authors at Boston University and Mechanobiologix (Newton, MA, USA)! Abstract: Emphysema is a debilitating disease that remodels the lung leading to reduced tissue stiffness. Thus, understanding emphysema progression requires assessing lung stiffness at both the tissue and alveolar scales. Here, we introduce an approach to determine multiscale tissue stiffness and apply it to precision-cut lung slices (PCLS). First, we established a framework for measuring stiffness of thin, disk-like samples....
IIVS Posters – SOT 2023 Annual Meeting
March 31, 2023IIVS presented several posters at SOT 2023. This post includes links to the full PDF versions of each poster presented. Application of a Performance Characterization Protocol for the Assessment of Normal and Diseased Cryopreserved Human Precision-Cut Lung Evaluation and Transferability of a New Approach Methodology to Address Photoallergy Evaluation of Complex Compounds in the UV-Vis Absorption Spectra General Behaviors of Surfactants in the Bovine Corneal Opacity and Permeability Modifications in the RhE Phototoxicity Assay to Evaluate Long-Lasting Cosmetic Products Optimization of an In Vitro Preclinical Screening...
62nd Annual Meeting of the Society of Toxicology
March 14, 2023IIVS is looking forward to exhibiting at the 62nd Annual Meeting of the Society of Toxicology! If attending, please visit us during ToxExpo at booth #834. ...
IIVS and Toxys Enter Into Agreement to Offer ToxTracker® for In Vitro Genetic Toxicity Evaluation
March 9, 2023The Institute for In Vitro Sciences (IIVS) and Toxys have entered into a license agreement that allows IIVS to offer the ToxTracker® assay. ToxTracker is an innovative in vitroassay allowing identification of the genotoxic and potentially carcinogenic properties of novel and existing drugs, (agro)chemicals, cosmetics and other substances without the use of animal testing....
March 2023 Newsletter
March 1, 2023IIVS is pleased to share that the PMI In Vitro Alternatives Laboratory in Neuchâtel, Switzerland is now GIVIMP certified. Good In Vitro Method Practices (GIVIMP) is an OECD guidance document that provides a framework for quality standards specific to in vitro laboratory operations....
Key Challenges and Recommendations for In Vitro Testing of Tobacco Products for Regulatory Applications: Consideration of Test Materials and Exposure Parameters
February 23, 2023The Institute for In Vitro Sciences (IIVS) is sponsoring a series of workshops to identify, discuss and develop recommendations for optimal scientific and technical approaches for conducting in vitro assays, to assess potential toxicity within and across tobacco and various next generation nicotine and tobacco products (NGPs), including heated tobacco products (HTPs) and electronic nicotine delivery systems (ENDS). The third workshop (24–26 February 2020) summarised the key challenges and made recommendations concerning appropriate methods of test article generation and cell exposure from...
Derivation of a Point of Departure from In Vitro Methods for use in Skin Sensitization Risk Assessment Pt 2
February 16, 2023This webinar explores the use of Non-Animal Methodologies to derive a Point of Departure (predicted LLNA EC3) which can be used to evaluate the skin sensitization potency as well as downstream use for risk assessment. Presenters include: Dr. Argel Islas-Robles (Study Director and Toxicologist, IIVS) and Dr. Andreas Natsch (Senior Research Fellow, Givaudan)....